Navigation Links
Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
Date:11/17/2010

HORSHAM, Pa., Nov. 17, 2010 /PRNewswire/ -- Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced that Bob Radie has been appointed President and Chief Executive Officer (CEO).  Thomas Beck, M.D., who was serving as interim Chief Executive Officer, will resume his role as Chief Medical Officer of the company.

Topaz Pharmaceuticals' lead product, ivermectin topical cream, is concluding Phase 3 clinical trials to support a new drug application for the treatment of head lice.  

"Bob's appointment follows a comprehensive selection process by the Board of Directors to identify the best leader to take Topaz Pharmaceuticals forward and maximize the value of its lead product, a novel formulation of ivermectin," said Robert D. Casale, non-executive Chairman of the Board.  "Bob's combination of business development experience as well as his expertise in successfully introducing new medicines into the commercial market is a great fit for Topaz as we prepare to report Phase 3 data on ivermectin topical cream for the treatment of head lice.  Bob's extensive pharmaceutical experience should prove highly beneficial to Topaz as the company continues to advance this novel product through the drug approval process."

Mr. Radie has over 25 years of experience in the pharmaceutical and biotechnology industries.  Most recently, he served as President and CEO of TransMolecular, Inc., a biotechnology company developing novel cancer diagnostic and treatment products.  He previously served as Chief Business Officer at Prestwick Pharmaceuticals, Inc. and Morphotek.  He played leading roles in the acquisition of Prestwick by Biovail Corp. in 2008 and Morphotek by Eisai, Inc. in 2007.  He has also served as senior vice president of strategic projects and planning at Vicuron Pharmaceuticals (acquired in 2005 by Pfizer).  Before joining Vicuron, Mr. Radie worked for Eli Lilly and Company,
'/>"/>

SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TOPAZ Technologies and ML Weekes & Company Announce Partnership
2. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
4. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
8. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
10. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Vanda Pharmaceuticals Appoints Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
(Date:7/28/2014)... and LONDON , July ... Collaboration aims to create and commercialize companion diagnostic using ... of IRESSA  for non-small cell lung cancer patients  ... therascreen   EGFR test and is planned to run on Rotor-Gene Q, ... Project enabled by AstraZeneca master framework agreement adds ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 According to the ... is a comprehensive guide that will help people get rid ... readers all the necessary information about heartburn and acid reflux. ... truth about heartburn , and risk factors for reflux disease. ... will help people get rid of symptoms of reflux disease ...
(Date:7/28/2014)... 2014 Building a sense of neighborhood ... Where personal outdoor space is not possible, building ... fun and exercise outside is important. That’s why ... quality commercial playground equipment from APCPLAY. , Old Buckingham ... Virginia. It is an historic tourist location of one ...
(Date:7/28/2014)... Los Angeles, Calif., July 27, 2014 - (PRWEB) July 28, ... world title in 12 months by earning the Masters Champion ... July 20, proving that age is no obstacle for this ... and win at the event hosted by the International Pole ... 10 to 63, traveling from 30 countries, took part in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dr. Alan Xenakis, ... “DOC X MD Funny Feelings.” The new book, DOC ... Feelings in a unique story telling style with humor and ... and motivational. The reader will find answers to those age-old ... running water make people pee? Why do mosquitoes bite some ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... doing the rounds that global warming in the East ... A novel research by an international team places ... malaria’s spread, along with other factors like drug and ... University of Michigan theoretical ecologist Mercedes Pascual, has contributed ...
... with danger, is also the color of blood, signaling perpetuation ... of blood on a daily basis to cater to patients ... Sunderland have set the ball rolling, campaigning and urging people ... the run-up to Easter. ,Take the case of ...
... suggests that patients on the newer medications for diabetics ... spent between $920 and $1,760 less on annual total ... lead author and the Merrell Dow professor of pharmacy ... of medical records data on patients who took thiazolidinediones ...
... between widely used childhood medicines and the risk of developing ... allergies, expose the kids to pets and dirt early. The ... is known as the hygiene hypothesis. , It ... fields and farm animals, leaves people more susceptible to a ...
... review of several studies conducted on cancer-causing chemicals has ... babies as a consequence of exposure to organochlorines//. Pesticides ... such chemicals and may be passed on to humans ... it can be indirectly passed on to human beings ...
... cancer is one of the deadliest diseases in UK. Symptoms ... a need to rush to the loo//. ,Hence ... to increase awareness about prostate cancer. Prostate cancer kills 220 ... UK. ,Mr Campbell has won the support ...
Cached Medicine News:Health News:New Diabetic Drugs More Effective than Older Ones 2Health News:A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm 2Health News:Parents Concerned About Pesticide And Cancer Risk To Babies 2
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Phaco chopper delicate rounded tip....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Medicine Products: